Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.

Lee JM, Miller A, Rose PG, AlHilli M, Washington C, John VS, Shah CA, Matsuo K, Siedel J, Miller DS, Hopp EE, O'Shea A, Chan JK, Bradford LS, Morse CB, Nagel CI, Rodabaugh KJ, Kohn EC, Moore KN, Liu JF

Open source

DOI: 10.1158/1078-0432.ccr-24-3877
Published: 2025 Jun 13
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-24-3877,
  title = {Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.},
  author = {Lee JM and Miller A and Rose PG and AlHilli M and Washington C and John VS and Shah CA and Matsuo K and Siedel J and Miller DS and Hopp EE and O'Shea A and Chan JK and Bradford LS and Morse CB and Nagel CI and Rodabaugh KJ and Kohn EC and Moore KN and Liu JF},
  year = {2025},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-24-3877},
  url = {https://doi.org/10.1158/1078-0432.ccr-24-3877}
}

RIS

TY  - JOUR
TI  - Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.
AU  - Lee JM
AU  - Miller A
AU  - Rose PG
AU  - AlHilli M
AU  - Washington C
AU  - John VS
AU  - Shah CA
AU  - Matsuo K
AU  - Siedel J
AU  - Miller DS
AU  - Hopp EE
AU  - O'Shea A
AU  - Chan JK
AU  - Bradford LS
AU  - Morse CB
AU  - Nagel CI
AU  - Rodabaugh KJ
AU  - Kohn EC
AU  - Moore KN
AU  - Liu JF
PY  - 2025
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-24-3877
UR  - https://doi.org/10.1158/1078-0432.ccr-24-3877
ER  -

APA

JM, L., A, M., PG, R., M, A., C, W., VS, J., CA, S., K, M., J, S., DS, M., EE, H., A, O., JK, C., LS, B., CB, M., CI, N., KJ, R., EC, K., KN, M., & JF, L. (2025). Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-24-3877

Source records

pubmed · retrieved 2026-09-27T01:36:57.338Z